Walgreens Boots Alliance (NASDAQ:WBA) Reaches New 52-Week Low at $17.53

Walgreens Boots Alliance, Inc. (NASDAQ:WBA - Get Free Report)'s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $17.53 and last traded at $17.57, with a volume of 2508833 shares changing hands. The stock had previously closed at $17.64.

Wall Street Analyst Weigh In

WBA has been the subject of a number of research reports. Bank of America reduced their price objective on Walgreens Boots Alliance from $23.00 to $22.00 and set an "underperform" rating for the company in a research note on Tuesday, March 26th. Morgan Stanley reduced their price objective on Walgreens Boots Alliance from $21.00 to $20.00 and set an "underweight" rating for the company in a research note on Monday, April 1st. Deutsche Bank Aktiengesellschaft reduced their price objective on Walgreens Boots Alliance from $23.00 to $22.00 and set a "hold" rating for the company in a research note on Wednesday, April 3rd. HSBC reissued a "reduce" rating and issued a $20.00 price objective (down previously from $27.00) on shares of Walgreens Boots Alliance in a research note on Tuesday, February 20th. Finally, Truist Financial reissued a "hold" rating and issued a $25.00 price objective on shares of Walgreens Boots Alliance in a research note on Monday, April 1st. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $24.36.

Walgreens Boots Alliance Stock Down 0.1 %

The stock has a fifty day moving average of $20.60 and a 200 day moving average of $21.98. The firm has a market capitalization of $15.21 billion, a P/E ratio of -2.52, a price-to-earnings-growth ratio of 1.09 and a beta of 0.73. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.66 and a quick ratio of 0.32.

Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The pharmacy operator reported $1.20 EPS for the quarter, topping analysts' consensus estimates of $0.82 by $0.38. The business had revenue of $37.05 billion for the quarter, compared to analyst estimates of $35.86 billion. Walgreens Boots Alliance had a positive return on equity of 12.11% and a negative net margin of 4.18%. Walgreens Boots Alliance's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.16 earnings per share. On average, research analysts anticipate that Walgreens Boots Alliance, Inc. will post 3.23 EPS for the current fiscal year.

Insider Buying and Selling at Walgreens Boots Alliance

In other news, Director Valerie B. Jarrett bought 4,456 shares of the stock in a transaction on Monday, January 29th. The shares were purchased at an average cost of $22.44 per share, for a total transaction of $99,992.64. Following the completion of the purchase, the director now directly owns 4,456 shares in the company, valued at approximately $99,992.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Valerie B. Jarrett bought 4,456 shares of the stock in a transaction on Monday, January 29th. The shares were purchased at an average cost of $22.44 per share, for a total transaction of $99,992.64. Following the completion of the purchase, the director now directly owns 4,456 shares in the company, valued at approximately $99,992.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Inderpal S. Bhandari acquired 3,000 shares of the firm's stock in a transaction that occurred on Thursday, April 11th. The shares were bought at an average price of $18.05 per share, for a total transaction of $54,150.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at approximately $54,150. The disclosure for this purchase can be found here. Insiders have bought a total of 13,456 shares of company stock worth $270,423 over the last ninety days. 17.40% of the stock is currently owned by company insiders.

Institutional Trading of Walgreens Boots Alliance

A number of hedge funds and other institutional investors have recently made changes to their positions in WBA. Vontobel Holding Ltd. grew its position in Walgreens Boots Alliance by 104.6% during the first quarter. Vontobel Holding Ltd. now owns 36,922 shares of the pharmacy operator's stock worth $1,752,000 after buying an additional 18,879 shares in the last quarter. Moors & Cabot Inc. grew its position in Walgreens Boots Alliance by 31.1% during the first quarter. Moors & Cabot Inc. now owns 20,791 shares of the pharmacy operator's stock worth $931,000 after buying an additional 4,931 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Walgreens Boots Alliance by 27.9% during the first quarter. Sequoia Financial Advisors LLC now owns 7,569 shares of the pharmacy operator's stock worth $339,000 after buying an additional 1,651 shares in the last quarter. Candriam Luxembourg S.C.A. grew its position in Walgreens Boots Alliance by 0.5% during the first quarter. Candriam Luxembourg S.C.A. now owns 63,483 shares of the pharmacy operator's stock worth $2,842,000 after buying an additional 310 shares in the last quarter. Finally, Baird Financial Group Inc. grew its position in Walgreens Boots Alliance by 14.2% during the first quarter. Baird Financial Group Inc. now owns 467,533 shares of the pharmacy operator's stock worth $20,932,000 after buying an additional 58,184 shares in the last quarter. 58.59% of the stock is currently owned by institutional investors.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.